SEC Filing Summary: Rexahn Pharmaceuticals, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Rexahn Pharmaceuticals, Inc. on December 26, 2007, reporting events occurring on December 24, 2007. The filing details the consummation of securities purchase agreements with various Korean entities and individual investors. Note: The request metadata references "Opus Genetics, Inc.," but the filing text explicitly identifies the registrant as Rexahn Pharmaceuticals, Inc.
Key Financial Metrics and Transaction Details
The company completed a private placement of equity securities resulting in the following:
- Total Gross Consideration: Approximately $6,800,022.60 (net proceeds after expenses).
- Common Stock Issued: 4,857,059 shares total.
- Warrants Issued: 1,071,436 shares total (excluding a separate 107,144 shares issued to a consultant).
- Warrant Terms: Exercise price of $1.80 per share; three-year term; includes "full ratchet" anti-dilution protection.
- Use of Proceeds: General corporate purposes.
Note: This filing does not provide revenue, profit, cash flow, margin, or debt metrics for the company's operations.
Material Changes and Transaction Breakdown
The following investors participated in the December 24, 2007 closing:
| Investor | Shares Issued | Warrants Issued | Consideration |
|---|---|---|---|
| KT&G Corporation | 2,142,858 | 428,572 | $3,000,001.20 |
| Rexgene Biotech Co., Ltd. | 714,286 | 142,857 | $1,000,000.40 |
| Jungwoo Family Co., Ltd. | 142,857 | 28,571 | $199,999.80 |
| Kumho Investment Bank | 357,143 | 71,429 | $500,000.20 |
| Individual Korean Investors | 1,500,015 | 300,003 | $2,100,021.00 |
Additionally, a warrant to purchase 107,144 shares was issued to a consultant for assistance in the placement.
Outlook, Risks, and Contingencies
Registration Rights and Penalties: The company entered into a Registration Rights Agreement requiring the filing of a shelf registration statement with the SEC within 60 days of listing on the American Stock Exchange (AMEX). Failure to file by this deadline triggers liquidated damages of 2% of the investment amount per month, plus 18% annual interest on unpaid damages.
Anti-Dilution Risk: The warrants contain "full ratchet" anti-dilution provisions. If the company issues common stock at a price below $1.80, the warrant exercise price will be reduced to that lower price, potentially causing significant dilution to existing shareholders.
Regulatory Status: The securities were sold in offshore transactions outside the U.S. to non-U.S. persons under Regulation S and Section 4(2) of the Securities Act. They are unregistered and cannot be resold in the U.S. without registration or an exemption.
Key Facts for Investor Verification
- Verify the company's current listing status on the AMEX to determine the deadline for the required shelf registration filing.
- Assess the potential dilution impact of the "full ratchet" anti-dilution provision if the company raises capital below $1.80 per share in the future.
- Confirm the actual net cash received versus the gross consideration reported, as expenses were deducted.
- Review the company's cash burn rate to determine how long the $6.8 million in proceeds will sustain operations.
- Clarify the discrepancy between the request metadata ("Opus Genetics") and the filing registrant ("Rexahn Pharmaceuticals").